Sex differences in vascular endothelial function and health in humans: impacts of exercise

Experimental Physiology

Volumn 101, Issue 2, 2016, Pages 230-242

  Green, Daniel J ^a,b   Hopkins, Nicola D ^b   Jones, Helen ^b   Thijssen, Dick H J ^b,c   Eijsvogels, Thijs M H ^b,c   Yeap, Bu B ^d,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e FIONA STANLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; CALCIUM CHANNEL; CONJUGATED ESTROGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ESTRADIOL; GESTAGEN; NITRIC OXIDE; PROSTACYCLIN; TESTOSTERONE; TETRAHYDROBIOPTERIN;

AGE; AGING; ARTERY COMPLIANCE; ARTERY DIAMETER; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIGITAL TONOMETRY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EQUIPOISE; EXERCISE; FEMALE; FLOW MEDIATED DILATATION; FOLLICULAR PHASE; FUNCTIONAL STATUS; HEALTH; HEART FAILURE; HEART OUTPUT; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LUTEAL PHASE; MALE; MENOPAUSE; MUSCLE STRENGTH; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; POSTMENOPAUSE; PREMENOPAUSE; PULSE WAVE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SHEAR STRESS; SMOOTH MUSCLE CELL; TONOMETRY; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

EID: 84977631679     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/EP085367     Document Type: Review

References (72)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R & Wassertheil-Smoller S; Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701–1712.
2. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM & McKinlay JB (2004). Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89, 5920–5926.
3. Armeni E, Stamatelopoulos K, Rizos D, Georgiopoulos G, Kazani M, Kazani A, Kolyviras A, Stellos K, Panoulis K, Alexandrou A, Creatsa M, Papamichael C & Lambrinoudaki I (2013). Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype. J Hypertens 31, 1998–2004.
4. Ashor AW, Lara J, Siervo M, Celis-Morales C & Mathers JC (2014). Effects of exercise modalities on arterial stiffness and wave reflection: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 9, e110034.
5. Åstrand H, Stålhand J, Karlsson J, Karlsson M, Sonesson B & Länne T (2011). In vivo estimation of the contribution of elastin and collagen to the mechanical properties in the human abdominal aorta: effect of age and sex. J Appl Physiol 110, 176–187.
6. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD & Bhasin S (2010). Adverse events associated with testosterone administration. N Engl J Med 363, 109–122.
7. Basaria S, Harman S, Travison TG, Hodis H, Tsitouras P, Budoff M, Pencina KM, Vita J, Dzekov C, Mazer NA, Coviello AD, Knapp PE, Hally K, Pinjic E, Yan M, Storer TW & Bhasin S (2015). Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 314, 570–581.
8. Black MA, Cable NT, Thijssen DHJ & Green DJ (2009). Impact of age, sex, and exercise on brachial artery flow-mediated dilation. Am J Physiol Heart Circ Physiol 297, H1109–H1116.
9. Carmina E, Orio F, Palombo S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB & Lobo RA (2006). Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119, 356.e1–356.e6.
10. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J & Deanfield JE (1994). Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24, 471–476.
11. Chakrabarti S, Morton JS & Davidge ST (2014). Mechanisms of estrogen effects on the endothelium. Can J Cardiol 30, 705–712.
12. Clarkson TB (2013). Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14, 373–384.
13. Clarkson TB, Melendez GC & Appt SE (2013). Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 20, 342–353.
14. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE & Hennekens CH (1987). Menopause and the risk of coronary heart disease in women. N Engl J Med 316, 1105–1110.
15. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG & Poole-Wilson PA (1995). 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92, 24–30.
16. Coronary Drug Project Research Group (1974). Factors influencing long-term prognosis after recovery from myocardial infarction—three year findings of the coronary drug project. J Chrn. Dis 27, 267–285.
17. David FL, Carvalho MHC, Cobra ALN, Nigro D, Fortes ZB, Rebouças NA & Tostes RCA (2001). Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 38, 692–696.
18. Engelen L, Bossuyt J, Ferreira I, van Bortel LM, Reesink KD, Segers P, Stehouwer CD, Laurent S & Boutouyrie P (2015). Reference values for local arterial stiffness. Part A: carotid artery. J Hypertens 33, 1981–1996.
19. FDA (2014). The Food and Drug Administration Is Committed to Determining Sex Differences in How Drugs Work. http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm131182.htm
20. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E & Wenger N; HERS Research Group (2002). Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288, 49–57.
21. Green DJ, Dawson EA, Groenewoud HMM, Jones H & Thijssen DHJ (2014). Is flow;mediated dilation nitric oxide mediated?: A meta-analysis. Hypertension 63, 376–382.
22. Green DJ, Jones H, Thijssen DHJ, Cable NT & Atkinson G (2011). Flow mediated dilation (FMD) and cardiovascular event prediction: does nitric oxide matter? Hypertension 57, 363–369.
23. Green DJ, Maiorana AJ, O'Driscoll G & Taylor R (2004). Topical Review: Effects of exercise training on vascular endothelial nitric oxide function in humans. J Physiol 561, 1–25.
24. Green DJ, Swart A, Exterkate A, Naylor LH, Black MA, Cable NT & Thijssen DHJ (2010). Impact of age, sex and exercise on brachial and popliteal artery remodelling in humans. Atherosclerosis 210, 525–530.
25. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE & Hennekens CH (1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335, 453–461.
26. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H & Ouchi Y (1995). Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92, 3431–3435.
27. Hodis HN, Mack WJ, Shoupe D, Azen SP, Standczyk FZ, Hwang-Levine J, Budoff MJ & Henderson VW (2014). Testing the menopausal hormone therapy timing hypothesis: the Early vs Late Intervention Trial with with Estradiol. Circulation 130, A13283.
28. Inaba Y, Chen JA & Bergmann SR (2010). Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of the brachial artery: a meta-analysis. Int J Cardiovasc Imag 26, 631–640.
29. Jensen-Urstad K & Johansson J (2001). Gender difference in age-related changes in vascular function. J Intern Med 250, 29–36.
30. Kang SM, Jang Y, Kim J-Y, Chung N, Cho S-Y, Chae JS & Lee J-H (2002). Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89, 862–864.
31. Kannel WB, Hjortland MC, McNamara PM & Gordon T (1976). Menopause and the risk of cardiovascular disease. Ann Intern Med 85, 447–452.
32. Kelly DM & Jones TH (2013). Testosterone: a vascular hormone in health and disease. J Endocrinol 217, 47–71.
33. Kling JM, Lahr BA, Bailey KR, Harman SM, Miller VM & Mulvagh SL (2015). Endothelial function in women of the Kronos Early Estrogen Prevention study. Climacteric 18, 187–197.
34. Knowlton AA & Lee AR (2012). Estrogen and the cardiovascular system. Pharmacol Ther 135, 54–70.
35. Layton J, Meier CR, Sharpless JL, Stürmer T, Jick SS & Brookhart M (2015). Comparative safety of testosterone dosage forms. JAMA Intern Med 175, 1187–1196.
36. Lekontseva O, Chakrabarti S & Davidge ST (2010). Endothelin in the female vasculature: a role in aging? Am J Physiol Regul Integr Comp Physiol 298, R509–R516.
37. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ & Celermajer DS (1998). Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 32, 1331–1335.
38. McCrohon JA, Walters WAW, Robinson JTC, McCredie RJ, Turner L, Adams MR, Handelsman DJ & Celermajer DS (1997). Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 29, 1432–1436.
39. Maffei S, Mercuri A, Zucchelli GC & Vassalle C (2006). Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women. Int J Cardiol 107, 194–199.
40. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ & Wallace RB (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310, 1353–1368.
41. Mendelhson ME & Karas RH (2005). Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583–1587.
42. Moreau KL, Hildreth KL, Meditz AL, Deane KD & Kohrt WM (2012a). Endothelial function is impaired across the stages of menopause transition in healthy women. J Clin Endocrinol Metab 97, 4692–4700.
43. Moreau KL, Meditz A, Deane KD & Kohrt WM (2012b). Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol 302, H1211–H1218.
44. Moreau KL, Stauffer BL, Kohrt WM & Seals DR (2013). Essential role of estrogen for improvements in vascular endothelial function with endurance exercise in postmenopausal women. J Clin Endocrinol Metab 98, 4507–4515.
45. Morgentaler A & Lunenfeld B (2014). Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male 17, 63–65.
46. New G, Timmins KL, Duffy SJ, Tran BT, O'Brien RC, Harper RW & Meredith IT (1997). Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 29, 1437–1444.
47. Ojeda NB, Intapad S & Alexander BT (2014). Sex differences in the developmental programming of hypertension. Acta Physiol 210, 307–316.
48. Ong PJL, Patrizi G, Chong WCF, Webb CM, Hayward CS & Collins P (2002). Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85, 269–272.
49. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepherd MK & Baron AD (2001). Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103, 1410–1415.
50. Pierce GL, Eskurza I, Walker AE, Fay TN & Seals DR (2011). Sex specific effects of habitual aerobic exercise on brachial arterty flow-mediated dilation in middle-aged and older adults. Clin Sci (Lond) 120, 13–23.
51. Polderman KH, Stehouwer CDA, van Kamp GJ, Schalkwijk CG & Gooren LJG (2000). Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 49, 648–650.
52. Pugh PJ, Jones TH & Channer KS (2003). Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24, 909–915.
53. Ras RT, Streppel MT, Draijer R & Zock PL (2013) Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 168, 344–351.
54. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE & Denison FC (2009). Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 53, 952–958.
55. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM & Ockene J; Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333.
56. Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ & Celermajer DS (2003). Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf) 59, 62–67.
57. Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ & Celermajer DS (2001). Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin Endocrinol (Oxf) 54, 175–181.
58. Sharma R, Oni OA, Gupta K, Chen K, Sharma M, Dawn B, Sharma R, parashara D, Savin VJ, Ambrose JA & Barua RJ (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 36, 2706–2715.
59. Sprung VS, Cuthbertson DJ, Pugh CJ, Aziz N, Kemp GJ, Daousi C, Atkinson G, Green DJ, Cable NT & Jones H (2013a). Exercise training in PCOS enhances FMD in the absence of changes in fatness. Med Sci Sports Exerc 45, 2234–2242.
60. Sprung VS, Cuthbertson DJ, Pugh CJA, Daousi C, Atkinson G, Aziz N, Kemp GJ, Green DJ, Cable T & Jones H (2013b). Nitric oxide-mediated cutaneous microvascular function is impaired in PCOS but can be improved by exercise training. J Physiol 591, 1475–1487.
61. Sprung VS, Jones H, Pugh CJA, Aziz N, Kemp GJ, Green DJ, Atkinson G, Cable NT & Cuthbertson DJ (2014). Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lund) 126, 67–74.
62. Tarhouni K, Guidot AL, Freidja ML, Toutain B, Henrion B, Baufreton C, Pinaud F, Procaccio V, Grimaud L, Loufrani L, Lenfant F, Arnal JF & Henrion D (2013). Key role of estrogens and endothelial estrogen receptor α in blood flow-mediated remodeling of resistance arteries. Arterioscler Thromb Vasc Biol 33, 605–611.
63. Thijssen DHJ, Rongen GA, van Dijk A, Smits P & Hopman MTE (2007). Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J Appl Physiol 103, 852–857.
64. Tinken TM, Thijssen DHJ, Black MA, Cable NT & Green DJ (2008). Conduit artery functional adaptation is reversible and precedes structural changes to exercise training in humans. J Physiol 586, 5003–5012.
65. Tinken TM, Thijssen DHJ, Hopkins ND, Dawson EA, Cable NT & Green DJ (2010). Shear stress mediates vascular adaptations to exercise training in humans. Hypertension 55, 312–318.
66. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS & Ho PM (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836.
67. Webb CM, McNeill JG, Hayward CS, Zeighler D & Collins P (1999). Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100, 1690–1696.
68. Wenner MM, Taylor HS & Stachenfeld NS (2013). Androgens influence microvascular dilation in PCOS through ET-A and ET-B receptors. Am J Physiol Endocrinol Metab 305, E818–E825.
69. Williams MRI, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K & Komesaroff PA (2001). Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab 86, 5389–5395.
70. Worboys S, Kotsopoulos D, Teede H, McGrath B & Davis SR (2001). Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 86, 158–161.
71. Yeap BB (2015). Testosterone and cardiovascular risk. Curr Opin Endocrinol 22, 193–202.
72. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L & Toivonen J (1998). The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 69, 883–888.